W e have examined with attention the comments of the letter to the Editor in regards to our recently published article (1), and want to thank its authors for their interest in our work.
vs. 6.58 ± 6.0; p = 0.507), left ventricular mass (63.72 ± 57.78; p = 0.252) and epicardial fat (5.37 vs. 5.92; p = 0.169) were not different; however, the levels of adiponectin were significantly higher in those MS patients being treated with ACEI and ARA (12.53 ± 2.93 vs. 10.23 ± 1.98; p = 0,02), though they continued to be lower than those subjects in the control group (12.53 ± 2.93 vs. 14.95 ± 3.87; p = 0.037). It is important to investigate the beneficial metabolic effects of this type of antihypertensive, using appropriate study designs. Since there were no high blood pressure subjects in our control group using hypertension medication, we consider that this possible effect of ACEI and ARA was not a limitation to achieve our objective.
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